LifeSensors Press Release

Abzyme Therapeutics Licenses SUMOpro from LifeSensors

Abzyme Therapeutics, LLC was founded to develop human therapeutic monoclonal antibodies. They have
licensed LifeSensors protein expression platform, SUMOproTM to further their monoclonal antibody production.

MALVERN, PA -- October 19, 2011 -- Abzyme Therapeutics, a new biotechnology company dedicated to developing
methods to generate human monoclonal antibodies for the treatment of disease, announced today that they have
entered into an exclusive agreement with LifeSensors to license their proprietary protein expression platform,
SUMOproTM. Enhanced protein expression is key to the evolution and development of antibodies and the LifeSensors
SUMOproTM technology is a protein expression platform that can dramatically enhance overall protein production
through increased protein translation, solubility, and stability.

"The use of Abzyme Therapeutics' systems and platforms will allow monoclonal antibodies to be used for the treatment
of Alzheimer's disease, cancer, autoimmune disease, and infectious diseases" said Dr. Tauseef Butt, co-founder and
Chair of Abzyme Therapeutics Board of Directors.

Abzyme is currently focused on treating Alzheimer's by developing proteolytic antibodies capable of hydrolyzing and
clearing beta-amyloids from the human blood stream. These antibodies are designed to hydrolyze multiple antigen
target molecules and overcome the problem of resistance, providing increased benefit at reduced doses. Alternatively,
the generation irreversibly and repeatedly of these antibodies in the future will be critical in the development of
treatments for cancers and other diseases.

Abzyme Therapeutics, LLC has established its headquarters in the Great Valley Technology Center, Malvern, PA and aims
to exploit their platforms for the development of novel therapeutic antibodies that will offer affordable medicines with
increased benefit, requiring reduced dosages. With therapeutic antibody evolution platforms based on intracellular
(iHUMab)/extracellular (eHuMab) genetic selection systems, Abzyme Therapeutics is capable of generating highly
diversified human antibody repertoires. For more information please visit www.abzymetx.com.

LifeSensors, Inc. is the leading producer of innovative research tools for the ubiquitin and ubiquitin-like protein
pathways. Its prokaryotic and eukaryotic protein expression platforms SUMOproTM and SUMOstarTM are used worldwide
to overcome bottlenecks in protein production. LifeSensors' technologies enable research once difficult to achieve by
using a wide variety of high quality tools including enzymes, substrates, and inhibitors. For more information please visit
www.lifesensors.com.

Contact:
LifeSensors, Inc.
Email: info@lifesensors.com
Phone: (610) 644-8845
www.lifesensors.com
Or
Abzyme Therapeutics, LLC
Dr. Hiep Tran, Chief Scientific Officer
Email: info@abzymetx.com
Phone (610) 990-7531

LifeSensors, Inc. 271 Great Valley Parkway Malvern, PA 19355 (P) 610.644.8845 (F) 610.644.8616 www.lifesensors.com

---